Some neurological disorders like Alzheimer’s disease are developmental health issues. Infections, chronic high blood pressure, genetic traits are factors that are usually attributed to the onset and worsening of this disorder. Clinicians are witnessing the symptoms of this disorder across a big chunk of population in the country. According to the Alzheimer’s Association, more than five million Americans are afflicted with the disease, which is the sixth leading cause of death in America. The numbers are expected to rise in the coming years as an increasing number of Americans would find themselves on the threshold of old age.
Not many treatment options are available for Alzheimer’s patients. Currently, physicians rely on clinical neuropathologic evaluation of amyloid-β (Aβ) peptide aggregates (plaques) and neurofibrillary tangles. A group of researchers based on the premise about the presence of the enzyme monoamine oxidase (MAO) in various kinds of mental illnesses including depression, attempted to find if the same could be used as a biomarker to diagnose Alzheimer’s in patients.
The scientists of the study, titled “Close Correlation of Monoamine Oxidase Activity with Progress of Alzheimer’s Disease in Mice, Observed by in Vivo Two-Photon Imaging” found that in brains of Alzheimer’s patients, the amyloid peptides accumulate to form oligomers and plaques deemed to be responsible for manifestation of the disease. Clinicians find it arduous to scan Aβ clustering in living patients as the current methods available to track down Aβ aggregation costs a lot, have problems of low resolution or require radiation. The study was published online in the journal ACS Central Science in December 2016.
Potential biomarker for Alzheimer’s disease identified
The scientists using an imaging tool to observe both Aβ and MAO simultaneously in mice found that MAO activity in mice increases with rise in Aβ plaques corresponding to development of Alzheimer’s in the patients. The authors also revealed three differing stages of MAO activity get modified along with progression of Alzheimer’s. The findings prompted the researchers to suggest that the MAO enzyme could serve as a biomarker for Alzheimer’s by making use of bodily fluids.
The observations made by the scientists are significant considering how Alzheimer’s disease is the most common form of dementia among mentally ill patients in the U.S. Though the disease is prevalent among people aged 65 years and more, some people in their 40s and 50s can also be afflicted with this disease. Elucidating on the commonality of the disorder, Dr. Heather Snyder, director of medical and scientific operations at the Alzheimer’s Association said, “As the 6th leading cause of death, Alzheimer’s disease is the only cause of death in the top 10 that we currently do not have a way to prevent, or to stop or slow its progression.”
Recovery road map for elderly people
Though not many effective medical interventions are available to cure and heal Alzheimer’s patients, timely diagnosis can help slow down the progression of the disease. If not detected early, the condition of the patients may deteriorate and cause them to suffer from slurred speech and impaired understanding.
If you or someone around you is suffering from Alzheimer’s or any other mental health problems, the experts at Florida Mental Health Helpline can help you in locating the best rehab facilities in Florida. You may call us at our 24/7 helpline number 866-846-5588 or chat online for further assistance on the most effective options in treatment for mental disorders in Florida.